Covetrus Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific
5.5.2022 23:01:00 EEST | Business Wire | Press release
Covetrus® (NASDAQ: CVET), a global leader in animal-health technology and services, today introduced Ascend—a powerful, cloud-based Practice Management software (PMS) built to enable veterinary practices across the United Kingdom, EMEA and Asia Pacific. Ascend improves efficiency, streamlines internal communication and collaboration, and creates a better experience for staff and clients.
In today’s high-demand environment, the introduction of Ascend addresses a clear and spoken technological need amongst the veterinary community. In a recent joint Covetrus and Vet Times survey, 76 percent of respondents expressed a desire for a better PMS that is easier-to-use and saves time.1
“At Covetrus, we are constantly listening to our customers and striving to address their needs through innovative technologies that fit seamlessly into their day-to-day operations,” said Georgia Wraight, Executive Vice President and President of Global Technology Solutions at Covetrus. “Ascend’s user-friendly, cloud platform was designed using customer insights and feedback, combined with Covetrus’ technological and industry expertise. With Ascend, we are thrilled to provide a one-stop shop on an intuitive platform that offers unparalleled functionality, along with the freedom to work from anywhere, at any time, on any device.”
Ascend offers a highly visual, dynamic interface that brings multiple systems together into one user-friendly platform - enabling stronger and better internal collaboration, as well as the ability to leverage the power of preferred third-party integrations, from scheduling and diagnostics, to billing and insurance, retail sales, and beyond.
“We chose Covetrus technology because they’re well-known and trusted for their expertise and quality in the practice management space,” said Emily Renton, Clinical Director, Veterinarian and Ascend User. “Ascend is an obvious choice for us and perfect for independent practices looking for a simple system that is intuitive, well-designed and knows how to make a vet’s life easier during the working day. I am so impressed with everything from the visuals, its integrations, how it helps us deal with clients in a smooth manner and how it’s all tied together. It certainly makes for a happier workforce and better collaboration between my staff.”
The introduction of Ascend comes on the heels of the successful beta period of Covetrus Pulse™ , an innovative cloud-based veterinary operating system (vOS) in the United States and Canada that unites the best of Covetrus’ technologies into an all-in-one cloud platform. Covetrus Ascend, like Pulse, is part of Covetrus’ ongoing mission to be the premier provider of ‘Connected Care’ solutions designed to empower veterinarians with care management technologies that help to streamline workflows, save time, and improve outcomes. Worldwide, approximately 28,000 practices are using Covetrus PMS and Prescription Management technology. With over 30+ years of experience in delivering innovative solutions for veterinarians across the globe, Ascend is another example of the Covetrus commitment to support and empower veterinarians from the front desk to the exam room, and beyond.
About Covetrus
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine with more than 5,700 employees serving over 100,000 customers around the globe. For more information about Covetrus, please visit Covetrus | Veterinary Software and Prescription Management Solutions.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.
1 Source: Vet Times + Covetrus Survey (437 surveyed and 90 respondents carried out across the UK), March 2022
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005902/en/
Contact information
Investor Contact
Nicholas Jansen
nicholas.jansen@covetrus.com
(207) 550-8106
Media Contact
Mona Downey
mona.downey@covetrus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IHS Towers Publishes 2025 Sustainability Report26.5.2026 13:34:00 EEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26.5.2026 13:01:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com
GlobalPlatform Launches Pavona: The First Open Silicon Distribution with Production-Grade Post-Quantum Cryptography26.5.2026 13:00:00 EEST | Press release
GlobalPlatform today launched Pavona, an open-source silicon distribution that delivers production-quality, certification-ready IP components and reference top-level designs — including the first openly available post-quantum cryptography (PQC) stack for embedded silicon. The distribution includes two successfully taped-out reference designs—a standalone chip root of trust and an integrated root of trust for chiplet architectures fabricated at TSMC 3nm (N3). Pavona provides a composable framework for building secure-by-default silicon aligned with FIPS 140-3 and Common Criteria certification requirements. Twelve founding members have already committed to the initiative, spanning semiconductor manufacturers, AI companies, academic research institutions, and IP providers. The full IP repository, top-level designs, continuous integration dashboards and getting-started documentation are available today at www.pavona.org. “The world faces a rising tide of cyber insecurity, with mounting cos
Croma Skincare – Where Science Meets Skin26.5.2026 12:43:00 EEST | Press release
With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines. Building on 50 years of experience in hyaluronic acid, Croma Pharma developed this skincare range to bridge the gap between in-clinic treatments and at-home care. The result is a streamlined portfolio that supports key skin needs such as hydration, glow, balance, and protection. The formulations combine high-performance actives including niacinamide, peptides, hyaluronic acid, and plant stem cells with lightweight, fast-absorbing textures that strengthen the skin barrier and enhance overall skin health. Hero products include: THE GLOW - a 20% stabilized vitamin C serum for radiance, antioxidant protection,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
